Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel
Source abstract
Abstract
Acute myocardial infarction (MI) caused by ischemia is the most common cause of cardiac dysfunction. While growth factor therapy is promising, the retention in the highly vascularized myocardium is limited and prevents sustained activation needed for adequate cellular responses. Here, we demonstrated the use of polyethylene glycol-fibrinogen (PF) hydrogels for sustained dual delivery of vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG-1) to enhance myocardial repair and function. VEGF and ANG-1 were incorporated in PF hydrogels and their in vitro characteristics were studied. Acute MI was generated in a rodent model with rats randomly assigned to 4 groups; sham, saline, PF and PF-VEGF-ANG1 (n=10 each group). Saline or hydrogel was injected in infarct and peri-infarct areas of the myocardium. After 4weeks, myocardial function was assessed using echocardiography. Tissue samples were harvested for Hematoxylin and Eosin, Masson Trichrome and capillary staining to assess the extent of fibrotic scar and arteriogenesis. Both VEGF and ANG-1 were released in a sustained and controlled manner over 30days. PF-VEGF-ANG1 treated animals showed the best improvement in cardiac function, highest degree of cardiac muscle preservation, and arteriogenesis. This study demonstrates that PF hydrogels can simultaneously provide mechanical support to attenuate adverse myocardial remodelling, and a pro-angiogenic benefit from the sustained VEGF and ANG1 delivery that culminates in a restorative effect following MI. The utility of this synergistic, biomaterial-based growth factor delivery may have clinical implications in the prevention of post-MI cardiac dysfunction. Statement of significance Acute myocardial infarction (MI) caused by ischemia is the most common cause of cardiac dysfunction. Here, we demonstrated the use of polyethylene glycol-fibrinogen (PF) hydrogels for sustained dual delivery of vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG-1) to enhance myocardial repair and function. Treated animals showed the best improvement in cardiac function, highest degree of cardiac muscle preservation, and arteriogenesis. This study demonstrates that PF hydrogels can simultaneously provide mechanical support to attenuate adverse myocardial remodelling, and a pro-angiogenic benefit from the sustained VEGF and ANG1 delivery that culminates in a restorative effect following MI.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Angiogenesis and VEGF in Cancer · Cardiac Fibrosis and Remodeling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy10.1161/01.CIR.101.25.2981 ↗
2. Tissue-engineered myocardial patch derived from extracellular matrix provides regional mechanical function10.1161/CIRCULATIONAHA.104.524355 ↗
3. Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair10.1016/j.biomaterials.2008.05.009 ↗
4. Cells, scaffolds, and molecules for myocardial tissue engineering10.1016/j.pharmthera.2004.10.003 ↗
5. Implantable left ventricular assist device. Approaching an alternative for end-stage heart failure. Implantable LVAD study group
6. Off-pump implant of the Jarvik 2000 ventricular assist device through median sternotomy10.1016/j.athoracsur.2007.02.004 ↗
7. Injectable biopolymers enhance angiogenesis after myocardial infarction10.1089/ten.2005.11.1860 ↗
8. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction10.1517/17425247.2013.739156 ↗
9. Designing cell-compatible hydrogels for biomedical applications10.1126/science.1214804 ↗
10. Hydrogels for tissue engineering10.1021/cr000108x ↗
11. Photopolymerizable hydrogels for tissue engineering applications10.1016/S0142-9612(02)00175-8 ↗
12. The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack10.1016/j.biomaterials.2013.10.058 ↗
13. Enhanced infarct stabilization and neovascularization mediated by VEGF-loaded PEGylated fibrinogen hydrogel in a rodent myocardial infarction model10.1016/j.biomaterials.2013.07.031 ↗
14. Vascular endothelial growth factor10.1161/ATVBAHA.108.179663 ↗
15. Vascular endothelial growth factor and angiogenesis10.1124/pr.56.4.3 ↗
16. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ10.1002/jgm.287 ↗
17. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts10.1006/jsre.1996.0226 ↗
18. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium10.1161/01.ATV.17.11.2793 ↗
19. Angiopoietin-1 induces sprouting angiogenesis in vitro10.1016/S0960-9822(98)70205-2 ↗
20. Increased vascularization in mice overexpressing angiopoietin-110.1126/science.282.5388.468 ↗
21. Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy10.1126/scitranslmed.3006666 ↗
22. Angiopoietin-1 protects the adult vasculature against plasma leakage10.1038/74725 ↗
23. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-110.1126/science.286.5449.2511 ↗
24. Structural investigation of PEG-Fibrinogen conjugates10.1016/j.actbio.2009.07.015 ↗
25. Vascular endothelial growth factor in heart failure10.1038/nrcardio.2013.94 ↗
26. Using bimodal MRI/fluorescence imaging to identify host angiogenic response to implant geometry10.1073/pnas.1502232112 ↗
27. Mechanisms of angiogenesis and arteriogenesis10.1038/74651 ↗
28. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation10.1074/jbc.273.46.30336 ↗
29. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease10.1111/j.1582-4934.2008.00254.x ↗
30. VEGF-receptor signal transduction10.1016/S0968-0004(03)00193-2 ↗
31. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium10.1016/j.bbrc.2003.09.111 ↗
32. Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model10.1002/jgm.439 ↗
33. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis10.1161/CIRCULATIONAHA.112.127472 ↗
34. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart10.1073/pnas.1018925108 ↗
35. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane10.1002/path.1711450103 ↗
36. Theoretical impact of the injection of material into the myocardium: a finite element model simulation10.1161/CIRCULATIONAHA.106.657270 ↗
37. Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction10.1371/journal.pone.0021571 ↗